April 1st 2024
Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Approves Bevacizumab Regimen for Ovarian Cancer Treatment After Surgery
June 13th 2018The FDA has approved bevacizumab (Avastin) for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of patients with advanced ovarian cancer following initial surgical resection.
Simple, Evidence-Based Decision Aid Can Help Previvors and Their Nurses Weigh Prevention Options
May 20th 2018When a woman learns she carries a BRCA gene mutation—and thus, in her lifetime, faces an 87% risk of developing breast cancer and a 63% risk of getting ovarian cancer—she has a difficult decision-making process ahead of her. One nurse created an easy-to-understand guide that explains all options and their pros and cons, for use by oncology nurses working with BRCA mutation carriers who do not have cancer—previvors.
Changes in Olaparib Indications Demonstrate Need for Best Practices for Nurses
May 19th 2018As the Food and Drug Administration continues to approve additional indications for olaparib (Lynparza), health care providers and caregivers should be aware of the potential adverse effects (AEs) associated with treatment.
Maintenance PARP Inhibitors for Ovarian Cancer Make Meaningful Impact on PFS
May 12th 2018With the approval of rucaparib in April 2018, there are now 3 PARP inhibitors approved for use in the maintenance setting for patients with ovarian cancer who are in a complete or partial response to platinum-based chemotherapy, and they are significantly improving progression-free survival.
FDA Approves Rubraca for Ovarian Cancer Maintenance Treatment
April 6th 2018The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.
Nurses Can Help in Multidisciplinary Management of HIV-Infected Cancer
February 28th 2018As part of a multidisciplinary team, nurses often reference guidelines to assist in treatment decisions for patients with cancer. Now, they also have guidance on how to treat individuals that comprise an underserved population of patients: those living with HIV and cancer.
Geography, Race, and Genetic Variation in Endometrial Cancer
February 21st 2018A study done at SUNY Downstate Hospital found that black women of Caribbean descent with type I or type II endometrial cancer expressed significant differences in genetic variations when compared with a nationwide population of patients with endometrial cancer.
USPSTF Recommends Against Ovarian Cancer Screening in Average- to Low-Risk Women
February 15th 2018Screening for ovarian cancer in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome has no benefit and may lead to harm due to false positives, according to a new review conducted by the US Preventive Services Task Force (USPSTF).
Ovarian Cancer Research Pivots Toward Combination Therapies
January 31st 2018Immunotherapy alone has not shown much success in treating ovarian cancer, despite success with other cancers, so researchers are now testing combinations of immunotherapy drugs with other agents to see if it enhances effectiveness.
Cisplatin May Cause Ototoxicity
January 12th 2018Cisplatin, a platinum-based chemotherapy agent that is used to treat testicular cancer, non-small cell lung cancer, bladder cancer, cervical cancer, ovarian cancer and head and neck cancer, has been found to cause a significant amount of hearing loss in patients, according to a recent article published in Nature Communications.
Maintenance Lynparza Tablets Approved in Ovarian Cancer
August 17th 2017Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.